stockmarketproxy
/
RYTMNasdaq SEC EDGAR

RHYTHM PHARMACEUTICALS, INC.

Pharmaceutical Preparations·BOSTON, MA·FY end 12/31·CIK 1649904
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$189.8M$130.1M$77.4M——
Gross Profit——————
Operating Income-$192.0M-$265.5M-$184.4M-$179.2M-$170.1M
Net Income-$196.5M-$260.6M-$184.7M-$181.1M-$69.6M
Operating CF-$115.7M-$113.9M-$136.2M-$173.4M-$146.0M
Capex$953.0K—$47.0K$281.0K$434.0K
Free Cash Flow-$116.6M—-$136.2M-$173.7M-$146.4M
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin-101.2%-204.0%-238.1%——
Net Margin-103.6%-200.3%-238.5%——
FCF Margin-61.5%—-175.9%——
R&D / Revenue88.2%182.9%174.3%——
Effective Tax-0.3%-0.1%-0.3%——
Debt / Equity0.734.98———
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
RYTM
36:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
RYTM
$18M
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
RYTM
-103.6%
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%